164 related articles for article (PubMed ID: 32479905)
21. Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.
Yang SY; Nguyen TT; Ung TT; Jung YD
Chonnam Med J; 2017 Sep; 53(3):178-186. PubMed ID: 29026705
[TBL] [Abstract][Full Text] [Related]
22. Recent progress in antibody-based therapeutics for triple-negative breast cancer.
Ning WJ; Liu X; Zeng HY; An ZQ; Luo WX; Xia NS
Expert Opin Drug Deliv; 2022 Jul; 19(7):815-832. PubMed ID: 35738312
[TBL] [Abstract][Full Text] [Related]
23. RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
Camp ER; Liu W; Fan F; Yang A; Somcio R; Ellis LM
Ann Surg Oncol; 2005 Apr; 12(4):273-81. PubMed ID: 15827676
[TBL] [Abstract][Full Text] [Related]
24. EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells.
Park JS; Khoi PN; Joo YE; Lee YH; Lang SA; Stoeltzing O; Jung YD
Int J Oncol; 2013 Mar; 42(3):1120-6. PubMed ID: 23337910
[TBL] [Abstract][Full Text] [Related]
25. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells.
Xia Y; Lian S; Khoi PN; Yoon HJ; Han JY; Chay KO; Kim KK; Jung YD
Int J Oncol; 2015 Apr; 46(4):1835-43. PubMed ID: 25625479
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
28. Antibody-Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer.
Al Jarroudi O; El Bairi K; Curigliano G; Afqir S
Cancer Treat Res; 2023; 188():1-27. PubMed ID: 38175340
[TBL] [Abstract][Full Text] [Related]
29. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract][Full Text] [Related]
30. Antibody drug conjugates for patients with breast cancer.
Medford A; Spring LM; Moy B; Bardia A
Curr Probl Cancer; 2021 Oct; 45(5):100795. PubMed ID: 34635342
[TBL] [Abstract][Full Text] [Related]
31. A new immunochemical strategy for triple-negative breast cancer therapy.
Lin CW; Zheng T; Grande G; Nanna AR; Rader C; Lerner RA
Sci Rep; 2021 Jul; 11(1):14875. PubMed ID: 34290315
[TBL] [Abstract][Full Text] [Related]
32. RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma.
Kim SA; Yoon TM; Lee DH; Park YL; Lee KH; Lim SC; Joo YE; Lee JK
Auris Nasus Larynx; 2014 Apr; 41(2):201-6. PubMed ID: 24287326
[TBL] [Abstract][Full Text] [Related]
33. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
[TBL] [Abstract][Full Text] [Related]
34. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model.
Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH
J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151
[TBL] [Abstract][Full Text] [Related]
35. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.
Wang SL; Weng DF; Wei HX; Huang Z; Lin RQ; Shi K; Lin JH
J Orthop Sci; 2021 Nov; 26(6):1100-1106. PubMed ID: 32972820
[TBL] [Abstract][Full Text] [Related]
37. Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma.
Kim SA; Lee KH; Lee DH; Lee JK; Lim SC; Joo YE; Chung IJ; Noh MG; Yoon TM
Int J Oncol; 2019 Aug; 55(2):513-526. PubMed ID: 31268163
[TBL] [Abstract][Full Text] [Related]
38. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder.
Cheng HL; Liu HS; Lin YJ; Chen HH; Hsu PY; Chang TY; Ho CL; Tzai TS; Chow NH
Br J Cancer; 2005 May; 92(10):1906-14. PubMed ID: 15870710
[TBL] [Abstract][Full Text] [Related]
39. Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Liu YZ; Han DT; Shi DR; Hong B; Qian Y; Wu ZG; Yao SH; Tang TM; Wang MH; Xu XM; Yao HP
World J Gastrointest Oncol; 2020 Nov; 12(11):1216-1236. PubMed ID: 33250957
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.
Lian S; Park JS; Xia Y; Nguyen TT; Joo YE; Kim KK; Kim HK; Jung YD
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]